Portrait Toxigenic Clostridium difficile assay, an isothermal amplification assay detects toxigenic C. difficile in clinical stool specimens

Expert Review of Molecular Diagnostics

Volumn 14, Issue 1, 2014, Pages 17-26

  Denys, Gerald A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C. difficile infections; Clostridium difficile; Diagnostic test; Helicase dependent amplification; Isothermal tcdB amplification; Nucleic acid amplification tests; Portrait Toxigenic C. difficile assay; Sensitivity, specificity; Toxigenic culture

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; HELICASE;

ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; COST; HUMAN; LABORATORY AUTOMATION; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PORTRAIT TOXIGENIC CLOSTRIDIUM DIFFICILE ASSAY;

CLOSTRIDIUM DIFFICILE; DIARRHEA; DNA, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACID AMPLIFICATION TECHNIQUES; SENSITIVITY AND SPECIFICITY;

EID: 84893082130     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.864239     Document Type: Article

References (75)

1. Voth DE, Ballard JD. Clostridium difficile toxins: Mechanism of action and role in disease. Clin. Microbiol. Rev. 18, 247-263 (2005
2. Viswanathan VK, Mallozzi MJ, Vedantam G. Clostridium difficile infection, an overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes 1(4), 234-242 (2010
3. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N. Engl. Med. 359, 1932-1940 (2008
4. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31, 431-455 (2010
5. Dubberke ER, Han Z, Bobo L et al. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections. J. Clin. Microbiol. 49, 2887-2893 (2011
6. Riggs MM, Sethi AK, Zabarsky TF et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-Term care facility residents. Clin. Infect. Dis. 45, 992-998(2007
7. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin. Infect. Dis. 46(Suppl. 1), S12-S18(2008
8. Loo VG, Bourgault A-M, Poirier L et al. Host and pathogen factors for Clostridium difficile infection and colonization. N. Engl. J. Med. 365, 1693-1703 (2011
9. Bartlett JG. Narrative review: The new epidemic of Clostridium difficile-Associated enteric disease. Ann. Intern. Med. 145, 758-764 (2006
10. Bauer MP, Notermans DW, van Benthem BH et al. ECDIS Study Group. Clostridium difficile infection in Europe: A hospital-based survey. Lancet 377, 63-73 (2011
11. Carroll KC, Bartlett JG. Biology of Clostridium difficile: Implications for epidemiology and diagnosis. Annu. Rev. Microbiol. 65, 501-521 (2011
12. Freeman J, Bauer MP, Baines SD et al. The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 23(3), 529-549 (2010
13. Kuijper EJ, Coignard B, Tull P et al. Emergence of Clostridium difficile associated disease in North America and Europe. Clin. Microbiol. Infect. 12, 2-18 (2006
14. Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-Associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 171(5), 466-472 (2004
15. Limbago BM, Long CM, Thompson AD et al. Clostridium difficile strains from community-Associated infections. J. Clin. Microbiol. 47, 3004-3007 (2009
16. Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int. J. Antimicrob. Agents 33, 42-45 (2009
17. McFarland LV. Emerging therapies for Clostridium difficile infections. Expert Opin. Emerg. Drugs 16, 425-439 (2011
18. O'Brien JA, Lahue BJ, Caro JJ et al. The emerging infectious challenge of Clostridium difficile-Associated disease in Massachusetts hospitals: Clinical and economic consequences. Infect. Control Hosp. Epidemiol. 28, 1219-1227 (2007
19. Bauer MP, Kuijper EJ, van Dissel T. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Treatment guidelines for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 15, 1067-1079 (2009
20. Butler M, Bliss D, Drekonja D et al. Effectiveness of early diagnosis prevention and treatment of Clostridium difficile infection. (Internet) AHRQ Comparative Effectiveness Reviews. Dec. report No. 11(12)-EHCO51-EF (2011
21. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108, 478-498 (2013
22. CDC. Vital signs: Preventing Clostridium difficile infection. MMWR Morb. Mortal Wkly Rep. 61(9), 157-162 (2012
23. Goorhuis A, Bakker D, Corver J et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction type 078. Clin. Infect. Dis. 47, 1162-1170 (2008
24. Akerland T, Persson I, Unemo M et al. Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J. Clin. Microbiol. 46, 1530-1533 (2008
25. Blossom DB, McDonald LC. The challenges posed by reemerging Clostridium difficile infection. Clin. Infect. Dis. 45, 222-227 (2007
26. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353, 2433-2441 (2005
27. Merrigan M, Venugopal A, Mallozzi M et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J. Bacteriol. 192, 4904-4911 (2010
28. Stabler RA, Dawson LF, Phua LT et al. Comparative analysis of BI/NAP1/ 027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. J. Med. Microbiol. 57, 771-775 (2008
29. Wary M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 1079-1084 (2005
30. Burns DA, Heap JT, Minton NP. The diverse sporulation characteristics of Clostridium difficile clinical isolates are not associated with type. Anaerobe 16, 618-622 (2010
31. Oka K, Osaki T, Hanawa T et al. Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases. J. Clin. Microbiol. 50, 915-921 (2012
32. Gerding DN, Johnson S. Does infection with specific Clostridium difficile strains or clades influence clinical outcome? Clin. Infect. Dis. 56, 1601-1603 (2013
33. Walk ST, Micic D, Jain R et al. Clostridium difficile ribotype does not predict severe infection. Clin. Infect. Dis. 55, 1661-1668 (2012).
34. Walker AS, Eyre DW, Wyllie DH et al. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin. Infect. Dis. 56, 1589-1600 (2013
35. Tenover FC, Novak-Weekley S, Woods CW et al. Impact on strain type on detection of toxigenic Clostridium difficile: Comparison of molecular diagnostic and enzyme immunoassay approaches. J. Clin. Microbiol. 48, 3719-3724 (2010
36. Waslawski S, Lo ES, Ewing SA et al. Clostridium difficile ribotype diversity at six health care institutions in the United States. J. Clin. Microbiol. 51, 1938-1941 (2013
37. Kim J, Pai H, Seo MR et al. Clinical and microbiologic characteristics of tcdA-negative variant Clostridium difficile infections. BMC Infect. Dis. 12, 109 (2012
38. Wilcox MH, Planche T, Fang FC. Point-Counterpoint: What is the role of algorithmic approaches for diagnosis of Clostridium difficile infectioñ J. Clin. Microbiol. 48, 4347-4353 (2010
39. Burnham CA, Carroll KC. Diagnosis of Clostridium difficile infection: An ongoing conundrum for clinicians and for clinical laboratories. Clin. Microbiol. Rev. 26(3), 604-630 (2013
40. Planche T, Wilcox M. Reference assays for Clostridium difficile infection: One or two gold standards? J. Clin. Pathol. 64, 1-5 (2011
41. Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: Its disease and toxins. Clin. Microbiol. Rev. 1(1), 1-18 (1988
42. Hink T, Burnham CA, Dubberke ER. A systematic evaluation of methods to optimize culture-based recovery of Clostridium difficile from stool specimens. Anaerobe 19, 39-43 (2013
43. Peterson LR, Robicsek A. Does my patient have Clostridium difficile infectioñ Ann. Intern. Med. 151, 176-179 (2009
44. Stamper PD, Alcabasa R, Aird D et al. Comparison of a commercial real-Time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J. Clin. Microbiol. 47, 373-378 (2009
45. Eckert C, Burghoffer B, Lalande V et al. Evaluation of the chromogenic agar chromID C. difficile. J. Clin. Microbiol. 51, 1002-1004 (2013
46. Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-Time PCR assay for C. difficile, tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J. Clin. Microbiol. 47, 3211-3217 (2009
47. Longtin Y, Trottier S, Brochu G et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin. Infect. Dis. 56, 67-73(2013
48. Kaltsas A, Simon M, Unruh LH et al. Clinical and laboratory characteristics of Clostridium difficile infection in patients with discordant diagnostic test results. J. Clin. Microbiol. 50, 1303-1307 (2012
49. Cullbreath K, Ager E, Nemeyer RJ et al. Evolution of testing algorithms at a university hospital for detection of Clostridium difficile infections. J. Clin. Microbiol. 50, 3073-3076 (2012
50. Gilligan PH. Is a two-step glutamate dehydrogenase antigen-cytotoxicity neutralization assay algorithm superior to the premier toxin A and B enzyme immunoassay for laboratory detection of Clostridium difficile? J. Clin. Microbiol. 46, 1523-1525 (2008
51. Novak-Weekley SM, Marlowe EM, Miller JM et al. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J. Clin. Microbiol. 48(3), 889-893 (2010
52. Reller ME, Lema CA, Peri TM et al. Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J. Clin. Microbiol. 45, 3601-3605 (2007
53. Ticehurst JR, Aird DZ, Dam LM et al. Effective detection of toxigenic by a two-step algorithm including tests for antigen and cytotoxin. J. Clin. Microbiol. 44, 1145-1149 (2006
54. Larson, AM, Fung AM, Fang FC. Evaluation of tcdB real-Time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J. Clin. Microbiol. 48, 124-130 (2010
55. Shetty N, Wren MW, Coen PG. The role of glutamate dehydrogenase for the detection of Clostridium difficile in faecal samples: A meta-Analysis. J. Hosp. Infect. 77, 1-6 (2011
56. Kvach EJ, Ferguson D, Riska PF et al. Comparison of BD GeneOhm Cdiff real-Time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. J. Clin. Microbiol. 48, 109-114 (2009
57. Peterson LR, Methta MS, Patel PA et al. Laboratory testing for Clostridium difficile infections: Light at the end of the tunnel. Am. J. Clin. Path. 136, 372-380 (2011
58. Terhes G, Urban E, Soki J et al. Comparison of a rapid molecular method, the BD GeneOhm Cdiff assay, to the most frequently used laboratory tests for detection of toxin-producing Clostridium difficile in diarrheal feces. J. Clin. Microbiol. 47, 3478-3481 (2009
59. Buchan BW, Mackey TL, Daly JA et al. Multicenter clinical evaluation of the Portrait Toxigenic C. difficile Assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens. J. Clin. Microbiol. 50(12), 3932-3936 (2012
60. Le Guern R, Herwegh S, Grandbastien B et al. Evaluation of a new molecular test, the BD Max Cdiff, for detection of toxigenic Clostridium difficile in fecal samples. J. Clin. Microbiol. 50, 3089-3090 (2012
61. Sunkesula VC, Kundrapu S, Muganda C et al. Does empirical Clostridium difficile infection (CDI) therapy result in false-negative CDI diagnostic test results? Clin. Infect. Dis. 57(4), 494-500 (2013
62. Hicke B, Pasko C, Groves B et al. Automation detection of toxigenic Clostridium difficile in clinical samples: Isothermal tcdB amplification coupled to array-based detection. J. Clin. Microbiol. 50(8), 2681-2687 (2012
63. Chapin KC, Dickenson RA, Wu F et al. Comparison of five assays for detection of Clostridium difficile toxin. J. Mol. Diagn. 13, 395-400 (2011
64. Pancholi P, Kelly C, Raczkowski M et al. Detection of toxigenic Clostridium difficile: Comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays. J. Clin. Microbiol. 50, 1331-1335 (2012
65. Swindells J, Brenwald N, Reading N et al. Evaluation of diagnostic tests for Clostridium difficile infection. J. Clin. Microbiol. 48, 606-608 (2010
66. Viala C, Le Monnier A, Maataoui N et al. Comparison of commercial molecular assays for toxigenic Clostridium difficile detection in stools: BD GeneOhm Cdiff, XPert C. difficile and Illumigene C. difficile. J. Microbiol. Methods 90, 83-85 (2012
67. Catanzaro M, Cirone J. Real-Time polymerase chain reaction testing Clostridium difficile reduces isolation time and improves patient management in a small community hospital. Am. J. Infect. Control 40, 663-666 (2012
68. Tenover FC, Baron EJ, Peterson LR et al. Laboratory diagnosis of Clostridium difficile infection: Can molecular amplification methods move us out of uncertainty? J. Mol. Diagn. 13, 573-582 (2011
69. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 1079-1084 (2005
70. Louie TJ, Miller MA, Mullane et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422-431 (2011
71. Wilcox MH, Shetty N, Fawley WN et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin. Infect. Dis. 55, 1056-1063 (2012
72. Johnson S, Homann SR, Bettin KM et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: A randomized, placebo-controlled trial. Ann. Intern. Med. 117, 297-302 (1992
73. Bobo L, Dubberke, ER, Tarr P et al. Fecal activated protein kinase 2 elevation is significantly associated with human Clostridium difficile infection. Program and Abstracts of the 48th Annual Meettingof the Infectious Disease Society of America. Arlington, VA, USA 2010 (Abstract 1415
74. Jiang ZD, DuPont HL, Garey K et al. A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am. J. Gastroenterol. 101, 1112-1116 (2006
75. Steiner TS, Flores CA, Pizarro TT et al. Fecal lactoferrin, interleukin-1 beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin. Diagn. Lab. Immunol. 4, 719-722 (1997